| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2025 | 0.02 |
—
|
| 2024 | 0.02 |
—
|
| 2023 | 0.02 |
—
|
| 2022 | 0.02 |
—
|
| 2021 | 0.02 |
—
|
| 2020 | ‡‡‡‡ |
|
| 2019 | 0.02 |
—
|
| 2018 | 0.02 |
—
|
| 2017 | 0.02 |
—
|
| 2016 | 0.02 |
—
|
| 2022 | 2023 | 2024 | Q'25 | |
|---|---|---|---|---|
| Cash | 28.86 | 28.30 | 35.57 | 34.44 |
| Receivables | 41.30 | 44.79 | 50.40 | 65.09 |
| Inventory | — | — | — | — |
| Other | — | — | — | — |
| 70.16 | 73.09 | 85.97 | 99.54 |
| 2022 | 2023 | 2024 | Q'25 | |
|---|---|---|---|---|
| Payables | 229.12 | 237.23 | 256.05 | 283.61 |
| ST’ Debt | 33.74 | 33.74 | 33.74 | 33.74 |
| Other | — | — | — | — |
| 262.86 | 270.97 | 289.79 | 317.35 |
| 10y | 5y | 3y | |
| Sales | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ |
| Earnings | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Book Value | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 50.13 | 55.29 | 53.76 | — |
—
|
| ’24 | 47.00 | 47.67 | 44.52 | 49.04 |
188.23
|
| ’23 | 46.27 | 49.19 | 44.59 | 46.75 |
186.79
|
| ’22 | 51.61 | 44.67 | 46.34 | 45.23 |
187.85
|
| ’21 | 49.08 | 51.46 | 49.29 | 49.73 |
199.55
|
| ’20 | 39.41 | 49.74 | 46.27 | 59.93 |
195.35
|
| ’19 | 55.02 | 43.13 | 47.75 | 52.29 |
198.18
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.72) | 9.28 | 6.64 | — |
—
|
| ’24 | (5.32) | 0.42 | 0.09 | 9.61 |
4.80
|
| ’23 | (11.61) | 6.71 | 1.35 | 6.17 |
2.62
|
| ’22 | (8.01) | 3.59 | 2.17 | 8.70 |
6.45
|
| ’21 | (6.04) | (7.84) | 4.33 | 10.64 |
1.09
|
| ’20 | (10.51) | 11.07 | (1.46) | 9.88 |
8.97
|
| ’19 | (6.95) | (0.27) | (0.35) | 5.76 |
(1.81)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.99) | 9.11 | 6.61 | — |
—
|
| ’24 | (5.36) | 0.36 | 0.06 | 9.51 |
4.58
|
| ’23 | (11.67) | 6.71 | 1.35 | 6.16 |
2.54
|
| ’22 | (8.01) | 3.52 | 2.13 | 8.69 |
6.33
|
| ’21 | (6.08) | (7.87) | 4.31 | 10.62 |
0.98
|
| ’20 | (10.55) | 10.95 | (1.49) | 9.83 |
8.74
|
| ’19 | (6.97) | (0.28) | (0.36) | 5.74 |
(1.88)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 0.03 | 0.15 | 0.02 | — |
—
|
| ’24 | (0.10) | (0.04) | (0.10) | 0.02 |
(0.23)
|
| ’23 | (0.08) | 0.08 | 0.08 | (0.11) |
(0.03)
|
| ’22 | 0.13 | (0.09) | (0.04) | 0.05 |
0.06
|
| ’21 | (0.03) | 0.14 | (0.05) | 0.12 |
0.19
|
| ’20 | (0.40) | 0.30 | 0.09 | 0.54 |
0.56
|
| ’19 | 0.19 | (0.22) | (0.07) | 0.06 |
(0.04)
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | ‡‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 2.12 | 1.49 | 1.26 | — | — | — |
Low Price
|
| — | ‡‡‡ | ‡‡‡‡ | ‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | 3.79 | 2.63 | 3.00 | — | — | — |
High Price
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 142 | 154 | 153 | — | — | — |
Employees
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.32 | 1.21 | 1.23 | — | — | — |
Revenue/Emp
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 187.85 | 186.79 | 188.23 | — | — | — |
Revenue
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 9.41% | 9.73% | 7.63% | — | — | — |
Gross Margin
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.10 | (0.56) | (5.26) | — | — | — |
EBT
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.12% | (0.30%) | (2.80%) | — | — | — |
EBT Margin
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.53 | (0.17) | (4.27) | — | — | — |
Net Income
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 20.34 | 17.09 | 17.01 | — | — | — |
Depreciation
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 9.21 | 9.15 | 9.23 | — | — | — |
Revenue/Sh
|
| — | ‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 0.06 | (0.03) | (0.23) | — | — | — |
Earnings/Sh
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.32 | 0.13 | 0.24 | — | — | — |
Cash Flow/Sh
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.01) | 0.00 | (0.01) | — | — | — |
Capex/Sh
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.31 | 0.12 | 0.22 | — | — | — |
Free CF/Sh
|
| — | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 5.01 | 5.26 | 4.88 | — | — | — |
Book Value/Sh
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 20.39 | 20.40 | 20.40 | — | — | — |
Shares
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 48.40 | 0.00 | 0.00 | — | — | — |
PE Ratio
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.26 | 0.27 | 0.17 | — | — | — |
PS Ratio
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.48 | 0.46 | 0.32 | — | — | — |
PB Ratio
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.49 | 0.51 | 0.37 | — | — | — |
EV/Sales
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 14.63 | 37.26 | 15.10 | — | — | — |
EV/FCF
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 6.45 | 2.62 | 4.80 | — | — | — |
Op' Cash Flow
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.13) | (0.08) | (0.22) | — | — | — |
Capex
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 6.33 | 2.54 | 4.58 | — | — | — |
FCF
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (192.70) | (197.88) | (203.82) | — | — | — |
Working Cap'
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 72.06 | 33.74 | 33.74 | — | — | — |
Total Debt
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 43.20 | 5.44 | (1.83) | — | — | — |
Net Debt
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 102.19 | 107.28 | 99.61 | — | — | — |
Sh' Equity
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.29% | (0.15%) | (1.20%) | — | — | — |
ROA
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.74% | 1.50% | (1.18%) | — | — | — |
ROIC
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.93% | (0.54%) | (4.51%) | — | — | — |
ROE
|
Atlantic American Corporation (AAME), a small Southeast-focused property and casualty insurer, trades at rock-bottom valuations—price-to-sales at 0.17 and price-to-book at 0.32—amid eroding profitability and catastrophe-driven losses, making it a classic contrarian value play overshadowed by market hype elsewhere. Recent earnings swung to a $4.3 million net loss in 2024 (EPS -$0.23), with gross margins plummeting 48% to 7.6% due to storm claims and inflation, dragging ROE to -4.5% versus industry norms. Yet, revenue has stabilized around $200 million with efficient operations (revenue per employee ~$1.3 million), hinting at underlying discipline eroded by cyclical headwinds.
The balance sheet offers a rare bright spot: debt slashed 53% to $33.7 million, yielding a net cash surplus and debt-to-equity under 20%—a fortress against rate cuts or shocks, unlike leveraged peers. Operating cash flow rebounded to $4.8 million, delivering a free cash flow yield over 10% at current prices, with negligible capex supporting potential dividends or growth.
While no insider buys and absent analyst targets signal caution, mean reversion in margins to 10% could flip EPS positive and spark 30-50% upside, but hurricane risks and prolonged slumps loom large. This battered name demands skepticism—stability on the sheet clashes with profit fragility, tilting asymmetry for patient risk-takers.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.